Impact of Sequential Ramucirumab Plus Docetaxel After PD-1 Inhibitors on Anti-PD-1 Antibody-Bound T-Cell Dynamics and Clinical Outcomes.
- DOI
- 10.1111/cas.70336
- Published
- 2026-01-30
- Container
- Cancer Sci
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1111/cas.70336,
title = {Impact of Sequential Ramucirumab Plus Docetaxel After PD-1 Inhibitors on Anti-PD-1 Antibody-Bound T-Cell Dynamics and Clinical Outcomes.},
author = {Matsumoto K and Naito Y and Shiroyama T and Tamiya M and Nishino K and Tamiya A and Okishio K and Kinehara Y and Kuge T and Mori M and Satoh S and Suzuki H and Tetsumoto S and Niki T and Suga Y and Osa A and Minami T and Koyama S and Takeda Y and Takakura N and Kumanogoh A.},
year = {2026},
journal = {Cancer Sci},
doi = {10.1111/cas.70336},
url = {https://doi.org/10.1111/cas.70336}
}RIS
TY - JOUR TI - Impact of Sequential Ramucirumab Plus Docetaxel After PD-1 Inhibitors on Anti-PD-1 Antibody-Bound T-Cell Dynamics and Clinical Outcomes. AU - Matsumoto K AU - Naito Y AU - Shiroyama T AU - Tamiya M AU - Nishino K AU - Tamiya A AU - Okishio K AU - Kinehara Y AU - Kuge T AU - Mori M AU - Satoh S AU - Suzuki H AU - Tetsumoto S AU - Niki T AU - Suga Y AU - Osa A AU - Minami T AU - Koyama S AU - Takeda Y AU - Takakura N AU - Kumanogoh A. PY - 2026 JO - Cancer Sci DO - 10.1111/cas.70336 UR - https://doi.org/10.1111/cas.70336 ER -
APA
K, M., Y, N., T, S., M, T., K, N., A, T., K, O., Y, K., T, K., M, M., S, S., H, S., S, T., T, N., Y, S., A, O., T, M., S, K., Y, T., N, T., & A., K. (2026). Impact of Sequential Ramucirumab Plus Docetaxel After PD-1 Inhibitors on Anti-PD-1 Antibody-Bound T-Cell Dynamics and Clinical Outcomes.. Cancer Sci. https://doi.org/10.1111/cas.70336
Source records
- europe-pmc · retrieved 2026-09-26T17:28:05.500Z